European Primary Care Cardiovascular Society
HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.
Changes in the structure of primary care delivery, and differences in content of telemedicine visits vs. office-based visits were observed in the USA during the COVID-19 pandemic.
ESC 2020 Mark Nidorf discusses the results of the LoDoCo2 trial, which evaluated the effects of the anti-inflammatory drug colchicine on CV events in patients with coronary artery disease.
ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.
This posthoc analysis of the ENGAGE AF-TIMI 48 trial demonstrated no difference in efficacy and safety of edoxaban vs. warfarin in AF patients with extreme body weight compared to middle body weight.
Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.
ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.
ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes
Attainment of 2016 guideline-recommended risk-based LDL-c goal was 54% and for 2019 risk-based LDL-c goal this was 33% in patients on lipid-lowering therapy in primary and secondary settings.
Participants who were overweight or obese had lower risk of total and CV mortality in a cohort of prediabetes and T2DM patients from the ORIGIN trial.
This study identified a metabolic signature, comprising 67 metabolites, that characterizes adherence to a Mediterranean diet and is associated with future CVD risk, independent of traditional risk factors.
ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.
